Advancing drug development in myelodysplastic syndromes
Abstract: Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the US Food and Drug Administration, (eg, luspaterce...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Elsevier
2025-03-01
|
| 丛编: | Blood Advances |
| 在线阅读: | http://www.sciencedirect.com/science/article/pii/S2473952924007511 |